REFRACTORY OVARIAN CARCINOMA
Clinical trials for REFRACTORY OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Supercharged immune cells take on Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis early-stage study tests a new treatment for ovarian cancer that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are trained in a lab to recognize and attack a protein called MUC1 found on cancer cells. The ma…
Matched conditions: REFRACTORY OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for tough ovarian cancer: CBX-12 trial launches
Disease control Recruiting nowThis study tests a new drug called CBX-12 in 40 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the drug can shrink tumors and to check its safety at two different dose levels. Participants receive the drug once every 21 days.
Matched conditions: REFRACTORY OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: Cybrexa Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:03 UTC